CLINICAL PUBLICATIONS
| SR. NO. | NAME OF PUBLISHED ARTICLE | LINK TO THE ARTICLE AND KNOW MORE | JOURNAL AND YEAR OF PUBLICATION | NUMBER OF PATIENTS | STUDY DESIGN | FOLLOW-UP | FIRST AUTHOR |
|---|---|---|---|---|---|---|---|
| Total Publications= 278 | |||||||
| CARDIOVASCULAR (Total=246 articles) | |||||||
|
Myval™ Transcatheter Heart Valve Replacement-Clinical Publications (Total=110 articles) |
|||||||
|
Original Research Articles (41) |
|||||||
| OR 41. | Early outcomes of the novel Myval THV series compared to SAPIEN THV series and Evolut THV series in individuals with severe aortic stenosis | NA | EuroIntervention (2024) | 384 out of 768 Patients | Prospective, RCT | 30 Days | Niels van Royen, The Netherlands |
| OR 40. | Learning Curve for Starting a Successful Single-Centre TAVR Programme with Multiple Devices: Early and Mid-Term Follow-Up | OR 40. | Journal of Clinical Medicine (2024) | 11 out of 122 Patients | Retrospective study | 3 years | Balázs Magyari, Hungary |
| OR 39. | Performance of balloon-expandable transcatheter bioprostheses in inoperable patients with pure aortic regurgitation of a native valve: The BE-PANTHEON international project | OR 39. | Cardiovascular Revascularization Medicine (2024) | 41 out of 144 Patients | Retrospective study | 1 year | Enrico Poletti, Italy |
| OR 38. | Initial experience with the Myval balloon expandable valve in Argentina | OR 38. | Revista Argentina de Cardioangiología Intervencionista (2024) | 300 Patients | Prospective multi-center registry | Post-procedure | Federico Blanco, Argentina |
| OR 37. | Early Outcomes of Transcatheter Aortic Valve Implantation With Next-generation Balloon-expandable Myval Transcatheter Heart Valve: Single-center Experience From Iraq | OR 37. | Journal of the Saudi Heart Association (2024) | 100 Patients | Prospective single-centre study | 30 Days | Khalid Amber, Iraq |
| OR 36. | German Experience with a Novel Balloon-Expandable Heart Valve Prosthesis for Transcatheter Aortic Valve Implantation Outcomes of the MYLAND (MYvaL germAN stuDy) Study | OR 36. | Journal of Clinical Medicine (2024) |
134 Patients | Investigator-initiated, multi-center, retrospective, observational study | 30 Days |
Timm Ubben, Germany |
| OR 35. | LANDMARK trial: Randomised non-inferiority comparison of early outcomes of newer generation Myval THV series with contemporary valves (Sapien and Evolut THV series) in real-world Patients with severe symptomatic native aortic stenosis | OR 35. | The Lancet (2024) |
768 Patients | RCT | 30 Days | Andreas Baumbach, UK |
| OR 34. | Clinical outcomes of the Myval transcatheter heart valve system in Patients with severe aortic valve stenosis: a two-year follow-up observational study | OR 34. | Archives of Medical Science (2024) |
207 Patients | Multi-centre, registry based, observational study | 2 Years | Teoman Kilic, Turkey |
| OR 33. | Multicenter Experience for Early and Mid-Term Outcome of MyVal Transcatheter Pulmonary Valve Implantation | OR 33. | Pediatric Cardiology (2024) |
53 Patients | Multi-center, observational study | 360 Days median follow-up | Mohamed Al Nasef, Saudi Arabia |
| OR 32. | Safety and effectiveness of the novel Myval Octacor transcatheter heart valve in severe, symptomatic aortic valve stenosis – A real world Indian experience (The OCTACOR India Study) | OR 32. | Cardiovascular Revascularization Medicine (2024) |
123 Patients | Multi-center, real-world observational registry | 30 Days | John Jose, India |
| OR 31. | Single-Center Experience with the Balloon Expandable Myval Transcatheter Aortic Valve System in Patients with Bicuspid Anatomy: Procedural and 30-Day Follow-Up | OR 31. | Journal of Clinical Medicine (2023) |
52 Patients | Retrospective, observational study |
30 Days | Balázs Magyari, Hungary |
| OR 30. | Clinical Outcomes Following Transcatheter Mitral Valve-in-Valve Replacement Using a Meril Myval Transcatheter Heart Valve | OR 30. | Heart, Lung and Circulation (2023) |
20 Patients | Retrospective, observational, single-centre study |
1 Year | Mullasari Ajit Sankardas, India |
| OR 29. | Comparing two-year outcomes of balloon expandable Myval and self- expanding Evolut R in severe aortic valve stenosis | OR 29. | International Journal of Cardiology (2023) |
58 out of 166 Patients |
Retrospective, single-center, observational, cohort analysis |
2 Years | Elisabetta Moscarella, Italy |
| OR 28. | Single center experience with the balloon‐expandable Myval transcatheter aortic valve system with the first 100 Patients: 30‐day and 1‐ year follow‐up | OR 28. | Catheterization and Cardiovascular Interventions (2023) |
100 Patients |
Retrospective, single-center study |
1 Year | Balázs Magyari, Hungary |
| OR 27. | Transcatheter Aortic Valve Replacement for Pure Native Aortic Valve Regurgitation: The PANTHEON International Project | OR 27. | JACC: Cardiovascular Interventions (2023) |
40 out of 69 Patients | Retrospective study | 1 Year | Enrico Poletti, Italy |
| OR 26. | Performance of the 32 mm Myval transcatheter heart valve for treatment of aortic stenosis in Patients with extremely large aortic annuli in real- world scenario: first global, multi-centre experience | OR 26. | Catheterization and Cardiovascular Interventions (2023) |
10 Patients | Retrospective, observational multi-center study | 30 Days | Andreas Holzamer, Germany |
| OR 25. | Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation | OR 25. | EuroIntervention (2023) | 113 Patients | International, multi-center, observational study | 1 Year | Juan Pablo Sánchez-Luna, Spain |
| OR 24. | Early Outcomes of a Next- Generation Balloon-Expandable Transcatheter Heart Valve – The Myval System: A Single-Center Experience from Serbia | OR 24. | Journal of Cardiology and Cardiovascular Medicine (2023) | 13 Patients | Retrospective, single center study | 30 Days | Darko Boljevic, Serbia |
| OR 23. | Assessing the Novel Myval Balloon-Expandable Valve with the Evolut Valve: A Propensity- Matched Study | OR 23. | Journal of Clinical Medicine (2023) |
120 out of 223 Patients | Retrospective, single-center study | 1 Year | Jonathan Halim, The Netherlands |
| OR 22. | Angiographic quantification of aortic regurgitation following Myval Octacor implantation: Independent core lab adjudication | OR 22. | International Journal of Cardiology (2023) |
125 Patients | Retrospective, core lab analysis | - | Ahmed Elkoumy, Ireland |
| OR 21. | Safety and performance parameters of the Myval transcatheter aortic valve bioprosthesis: The SAPPHIRE prospective registry | OR 21. | Cardiovascular Revascularization Medicine (2023) |
100 Patients | Single-arm, prospective registry | 2 Years | Luca Testa, Italy |
| OR 20. | One-year outcomes after Myval implantation in Patients with bicuspid aortic valve stenosis-a multi-centre real-world experience | OR 20. | Journal of Clinical Medicine (2023) |
62 Patients | Retrospective multi-centre study | 13.5 months median follow-up | Ahmed Elkoumy, Ireland |
| OR 19. | Latest iteration balloon and self-expandable transcatheter valves for severe bicuspid aortic stenosis: The TRITON study | OR 19. |
Revista Española de Cardiología |
122 out of 360 Patients | Multi-centre, retrospective registry | 30 Days | Ignacio J Amat-Santos, Spain |
| OR 18. | Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in Patients with bioprosthetic left side heart valves failure:1-year follow-up from a multi-center experience | OR 18. | International Journal of Cardiology (2023) | 97 Patients | Prospective, multi-centre study | 1 Year | Elisabetta Moscarella, Italy |
| OR 17. | Transcatheter aortic valve implantation: a report on Serbia’s first systematic program | OR 17. | Frontiers in Cardiovascular Medicine (2022) |
13 out of 56 Patients | Cohort study | 30 Days | Darko Boljevic, Serbia |
| OR 16. | Balloon-expandable TAVR bioprostheses: area or perimeter sizing? A prospective pilot study | OR 16. | Journal of Interventional Cardiology (2022) | 60 Patients | Prospective, single-centre study | 1 Year | Jonathan Halim, The Netherlands |
| OR 15. | Short-term outcome after transcatheter aortic valve replacement with a novel balloon-expandable valve | OR 15. | Netherlands Heart Journal (2022) |
120 Patients | Prospective, single-centre study | 6 Months | Jonathan Halim, The Netherlands |
| OR 14. | Transcatheter mitral valve-in-valve implantation with the balloon expandable Myval device | OR 14. | Journal of Clinical Medicine (2022) |
11 Patients | Multi-centre, retrospective study | 6 Months | Sara Blasco-Turrión, Spain |
| OR 13. | Transcatheter aortic valve implantation for severe bicuspid aortic stenosis- 2 years follow up experience from India |
OR 13. | Frontiers in Cardiovascular Medicine (2022) |
70 BAV Patients of 287 |
Multi-centre study | 2 Years | Vijay Kumar, India |
| OR 12. | Clinical comparison of a novel balloon-expandable versus a self-expanding transcatheter heart valve for the treatment of Patients with severe aortic valve stenosis: the EVAL Registry | OR 12. | Journal of Clinical Medicine (2022) |
58 of 166 Patients |
Retrospective, single-centre study | 6 months | Monica Barki, Italy |
| OR 11. | Feasibility of precise commissural and coronary alignment with balloon-expandable TAVI | OR 11. | Revista Española de Cardiología (2022) |
10 Patients | Prospective study | 1 Month | Sandra Santos-Martınez, Spain |
| OR 10. | Safety and efficacy of Myval implantation in Patients with severe bicuspid aortic valve stenosis-a multi-center real world experience |
OR 10. | Journal of Clinical Medicine (2022) |
68 Patients | Retrospective study | 30 Days | Ahmed Elkoumy, Ireland |
| OR 9. | First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study | OR 9. | Herz Cardiovascular Diseases (2021) |
25 Patients | Retrospective study | 3 Months | Ali Rıza Akyüz, Turkey |
| OR 8. | Myval™ versus alternative balloon-and self-expandable transcatheter heart valves: A central core lab analysis of conduction disturbances | OR 8. | International Journal of Cardiology (2021) | 135 out of 1131 Patients |
Central corelab analysis, retrospective registry | 1 Year | Santos Martinez S, Spain |
| OR 7. | Early multicenter experience of a new balloon-expandable Myval™ transcatheter heart valve in dysfunctional stenosed right ventricular outflow tract conduits | OR 7. | Annals of Pediatric Cardiology (2021) |
7 Patients | Retrospective, multi-centre study | Median follow-up 16 months | Muthukumaran C Sivaprakasam, India |
| OR 6. | Next-generation balloon-expandable Myval™ transcatheter heart valve in low-risk aortic stenosis Patients | OR 6. | Catheterization and Cardiovascular Interventions (2021) |
100 Patients | Retrospective, multi-center registry | 30 Days | Mario Garcia-Gomez, Spain |
| OR 5. | Early clinical and haemodynamic matched comparison of balloon-expandable valves | OR 5. | Heart (2021) | 130 of 416 Patients |
Prospective study | 30 Days | Jose R Delgado-Arana, Spain |
| OR 4. | Operator preference and determinants of size selection when additional intermediate-size aortic transcatheter heart valves are made available | OR 4. | International Journal of Cardiology (2021) |
1115 Patients | Retrospective survey | - | Hideyuki Kawashima, Ireland |
| OR 3. | Quantitative angiographic assessment of aortic regurgitation after transcatheter aortic valve implantation among three balloon-expandable valves | OR 3. | Global Heart (2021) | 108 out of 744 Patients | Retrospective, multi-center study | Post- implantation aortography | Hideyuki Kawashima, Ireland |
| OR 2. | Single-center experience of 105 minimalistic transfemoral transcatheter aortic valve replacement and its outcome | OR 2. | Indian Heart Journal (2021) | 105 Patients | Single-center, retrospective study | 30 Days | Ravinder Singh Rao, India |
| OR 1. | First-in-human evaluation of a novel balloon-expandable transcatheter heart valve in Patients with severe symptomatic native aortic stenosis: the MyVal-1 study | OR 1. | EuroIntervention (2020) |
30 Patients | First-in-human, prospective, multi-center, single-arm, open-label study | 1 Year | Samin K. Sharma, USA |
| Abstracts (10) | |||||||
| AB 10. | Conduction Disturbances and Permanent Pacemaker Implantation After Myval Transcatheter Heart Valve or Contemporary Standard Valves (Sapien and Evolut) Implantation: Insights From the LANDMARK Trial | AB 10. | JACC: Cardiovascular Interventions (2024) |
352 out of 706 Patients | Prospective randomized trial |
30 Days | Pieter Smits, The Netherlands |
| AB 9. | Predictors of Conduction System Disturbances Resulting in a New Permanent Pacemaker Implantation Within the LANDMARK Trial | AB 9. | JACC: Cardiovascular Interventions (2024) |
352 out of 706 Patients | Prospective randomized trial |
30 Days | Pieter Smits, The Netherlands |
| AB 8. | Comparison of the Self-Expandable Acurate Neo 2 and the New Balloon-Expandable Myval Series Transcatheter Heart Valve at 4-Year Follow-Up | AB 8. | JACC: Cardiovascular Interventions (2024) |
401 out of 545 Patients | Multicentric analysis | 4 Years | Akash Jain, Spain |
| AB 7. | Win Ratio Analysis of the LANDMARK Trial: Myval Transcatheter Heart Valve vs Contemporary Standard Valves (Sapien and Evolut) in Patients With Severe Aortic Stenosis | AB 7. | JACC: Cardiovascular Interventions (2024) |
768 Patients | Multicenter, randomized, non-inferiority trial |
30 Days | Akihiro Tobe, Ireland |
| AB 6. | Commissural/Coronary Alignment with the Novel Myval™ Octacor THV-The Octa Align Technique | AB 6. | JACC: Cardiovascular Interventions (2023) |
30 Patients | - | - | Pruthvi C. Revaiah, Ireland |
| AB 5. | Early single-center experience with Meril’s Myval transcatheter heart valve | AB 5. | JACC: Cardiovascular Interventions (2022) |
39 Patients | Single-centre, single-arm, open label, prospective registry |
30 Days | Alberto Colella Cervone, Brazil |
| AB 4. | Safety and efficacy of Myval™ transcatheter heart valve for treatment of severe symptomatic aortic stenosis at 30‐days | AB 4. | Catheterization and Cardiovascular Intervention (2020) |
7 Patients | Retrospective, cohort study | 1 Month | Nayef A. Al Asiri, Saudi Arabia |
| AB 3. | Implant of Myval transcatheter aortic valve in Patients with severe aortic stenosis | AB 3. | Structural Heart (2020) | 5 Patients | Prospective study | 6 Months | Andrea Janet Robaina Barrios, Venezuela |
| AB 2. | Clinical and haemodynamic outcomes of Patients who underwent transcatheter mitral valve-in-valve replacement: one- month results | AB 2. | The American Journal of Cardiology (2020) |
10 Patients | - | 1 Month | Ravinder Singh Rao, India |
| AB 1. | Evaluation of balloon expandable transcatheter heart valve in the treatment of severe symptomatic native aortic stenosis: the first-in human MyVal-1 study | AB 1. | Structural Heart (2020) | 100 Patients |
First-in-man, prospective, multi-centre, single-arm study |
1 Month | Ravinder Singh Rao, India |
| Case Reports (24) | |||||||
| CR 24. | Transcatheter pulmonary valve implantation with custom-made 35-mm Myval™ transcatheter heart valve | CR 24. |
Annals of Pediatric Cardiology (2024) |
1 Patient | - | Post- procedural | Sivasubramanian Ramakrishnan, India |
| CR 23. | Coronary alignment by OctaAlign technique using Myval Octacor transcatheter heart valve in a bicuspid aortic valve | NA |
Journal of Cardiovascular Intervention (2024) |
1 Patient | - | Post- procedural | Raja Ramesh Nukavarapu, India |
| CR 22. | Direct aortic TAVI via anterior right mini thoracotomy using 32 mm myval for pure aortic regurgitation | CR 22. |
Journal of Cardiothoracic Surgery (2024) |
1 Patient | - | Post- procedural | Firas Aljanadi,UK |
| CR 21. | Technical Aspects for Transcatheter Aortic Valve Replacement with the Novel Balloon-Expandable Myval Octacor | CR 21. |
JACC: |
1 Patient | - | Post-procedural | Alfonso Ielasi, Italy |
| CR 20. | Transcatheter aortic valve implantation for aortic regurgitation in HeartMate II supported patient using Myval THV: a case report | CR 20. | Oxford Medical Case Reports (2023) |
1 Patient | - | 1 Year | Mohamad Hamieh, Lebanon |
| CR 19. | Case report: A complex case of valve-in-valve TAVI and left bundle branch pacing for severe aortic regurgitation with partially corrected type A aortic dissection and low ejection fraction | CR 19. | Frontiers in Cardiovascular Medicine (2023) | 1 Patient | - | 1 Year | Peter Marko Mihailovič, Slovenia |
| CR 18. | Pulmonary valve replacement in a large and tortuous right ventricle outflow tract with a 32 mm Myval valve under local anesthesia: challenges and technical considerations: a case report | CR 18. | European Heart Journal Case Reports (2023) | 1 Patient | - | 3 Months | Ali Houeijeh, France |
| CR 17. | Case report: a novel surgical technique for rapid valve-in-ring implantation into the native aortic annulus during left ventricular assist device implantation | CR 17. | Frontiers in Cardiovascular Medicine (2023) |
1 Patient | - | 6 Months | Yuriy Pya, Kazakhstan |
| CR 16. | Left ventricular assist device implantation combined with direct transaortic transcatheter valve-in-annular stent implantation after rescue mechanical Bentall procedure, a case report | CR 16. | BMC Journal of Cardiothoracic Surgery (2023) |
1 Patient | - | Post-procedural | Yuriy Pya, Kazakhstan |
| CR 15. | In-series transcatheter aortic valve replacement-in-transcatheter aortic valve replacement: ACURATE neo transcatheter heart valve degeneration successfully managed with Myval, avoiding coronary flow obstruction-a case report | CR 15. | Structural Heart (2023) | 1 Patient | - | 1 Month | Joao Felipe Barros de Toledo, Brazil |
| CR 14. | Redo-transcatheter aortic valve implantation in a patient at high risk of coronary obstruction due to sinus sequestration | CR 14. | European Heart Journal (2023) | 1 Patient | - | Post-procedural | Ying-Hwa Chen, Taiwan |
| CR 13. | Under-deployed TAVI with occluded left-main and severe aortic regurgitation; bailout chimney-in-chimney stenting and aggressive post-dilatation saves the day | CR 13. | Clinical Case Reports (2022) | 1 Patient | - | 1 Week | Pandula Athauda-arachchi, Sri Lanka |
| CR 12. | Transcatheter mitral valve-in-valve replacement transeptally using a novel balloon-expandable device | CR 12. | Journal of Cardiac Surgery (2022) |
1 Patient | - | Procedural Details | Maria Drakopoulou, Greece |
| CR 11. | Transcatheter treatment tricuspid regurgitation by valve-in-ring implantation with a novel balloon-expandable Myval™ THV | CR 11. | Clinical vignette Kardiologia Polska (2022) | 1 Patient | - | Procedural Details | Hüseyin Ayhan, Turkey |
| CR 10. | Pulmonary percutaneous valve implantation in large native right ventricular outflow tract with 32mm Myval transcatheter heart valve | CR 10. | Catheterization and Cardiovascular Interventions (2021) |
1 Patient | - | 1 Year | Alejandro Rodríguez Ogando, Spain |
| CR 9. | Transcatheter aortic valve implantation for aortic insuffiency in Patients with left ventricular assistance | CR 9. | Giornale Italiano di Cardiologia (2021) |
1 Patient | - | Post-procedural | Marco B. Ancona, Milan, Italy |
| CR 8. | First-in-man valve-in-valve with the new balloon-expandable Myval™ transcatheter heart valve in a failed sutureless perceval bioprosthesis | CR 8. | Journal of Cardiac Surgery (2021) |
1 Patient | - | 30 Days | Igor Belluschi, Italy |
| CR 7. | Transcatheter tricuspid valve-in-valve implantation with a novel balloon expandable Myval THV | CR 7. | The Annals of Thoracic Surgery (2021) |
1 Patient | - | 1 Month | Bilge Duran Karaduman, Turkey |
| CR 6. | Tip-to-base lampoon to prevent left ventricular outflow tract obstruction in a valve-in-ring transcatheter mitral valve replacement: first LAMPOON procedure in turkey and first LAMPOON case for transseptal Myval™ implantation | CR 6. | Anatolian Journal of Cardiology (2021) |
1 Patient | - | 1 Month | Teoman Kılıç, Turkey |
| CR 5. | Successful management of left main coronary artery obstruction following transcatheter aortic valve implantation | CR 5. | IHJ Cardiovascular Case Reports (2020) |
1 Patient | - | Procedural Details | Viveka Kumar, India |
| CR 4. | Myval™ and mini-chimney stenting to prevent coronary obstruction during full root stent-less aortic valve-in-valve procedure | CR 4. | Cardiovascular Revascularization Medicine (2020) |
1 Patient | - | 6 Months | Alfonso Ielasi, Italy |
| CR 3. | Simultaneous percutaneous coronary intervention and transcatheter aortic valve implantation in a very high-risk octogenarian patient-what’s ideal time? |
CR 3. | IHJ Cardiovascular Case Reports (2020) |
1 Patient | - | 8 Months | Pankaj Jariwala, India |
| CR 2. | First transcatheter pulmonary valve implantation-an Indian made valve | CR 2. | IHJ Cardiovascular Case Reports (2020) |
1 Patient | - | 6 Months | Muthukumaran Chinnasamy Sivaprakasam, India |
| CR 1. | Successful transcatheter aortic valve replacement in a kidney allograft patient on rapamycin | CR 1. | Indian Journal of Transplantation (2019) | 1 Patient | - | Procedural Details | Aashish Chopra, India |
| Case Series (9) | |||||||
| CS 9. | Transcatheter aortic valve replacement in patients with a pre-existing prosthetic mitral valve: a single center experience with two cases | CS 9. |
The Egyptian Heart Journal |
2 Patients | - | - | Oyewole A. Kushimo, Nigeria |
| CS 8. | A new simple technique for stabilizing the guidewire position within the left ventricle during transcatheter mitral valve‐in‐valve implantation | CS 8. |
Catheterization and Cardiovascular Interventions (2024) |
2 Patients | - | Post-procedure | Kothandam Sivakumar, India |
| CS 7. | Transcatheter Aortic Valve Implantation in Two High-Risk Patients with Low Coronary Ostial Heights Using the Novel Balloon Expandable MyvalTM Valve | CS 7. |
Journal of Cardiology |
2 Patients | - | 1 Month | Raja Ramesh N, India |
| CS 6. | Case report: Transcatheter tricuspid valve-in-valve implantation using novel balloon-expandable aortic valve with 1 year follow-up | CS 6. |
Frontiers in Cardiovascular |
5 Patients | - | 1 Year | Abdurashid Mussayev, Kazakhstan |
| CS 5. | Transcatheter mitral valve replacement (TMVR) for degenerated mitral valve bioprosthesis-A case series | CS 5. |
IHJ Cardiovascular Case Reports |
5 Patients | - | 1 Month | Viveka Kumar, India |
| CS 4. | TAVR in a large bicuspid anatomy using the XL-Myval™ 32mm | CS 4. | Frontiers in Cardiovascular Medicine (2022) | 3 Patient | - | 30 Days | Ahmed Elkoumy, Ireland |
| CS 3. | Two case reports of transcatheter valve-in-valve implantation of Sapien 3 and MyVal in degenerated biological tricuspid prosthesis valves | CS 3. |
European Heart Journal |
2 Patients | - | 6 Years | Rebekka Vibjerg Jensen, Denmark |
| CS 2. | First experiences with Myval™ transcatheter heart valve system in the treatment of severe pulmonary regurgitation in native right ventricular outflow tract and conduit dysfunction |
CS 2. |
Cardiology in the Young |
9 Patients | - | 9.8 months mean follow up | Ender Odemis, Turkey |
| CS 1. | Trans-catheter valve-in-valve implantation with a novel balloon expandable device in Patients with bioprosthetic heart valve failure: A case series | CS 1. |
Cardiovascular Revascularization Medicine |
5 Patients | - | Post-procedural | Alfonso Ielasi, Italy |
| Editorial/ Editorial Letters (09) | |||||||
| EL9. | BASELINE trial: update in study design | EL9. | American Heart Journal (2024) | - | Protocol update |
Rutger-Jan Nuis, The Netherlands |
|
| EL8. | Novel 35-mm Balloon-Expandable Transcatheter Aortic Valve Replacement | EL8. | JACC: Cardiovascular Interventions (2024) |
- | - | - | John Jose, India |
| EL7. | LANDMARK trial: Update in study protocol | EL7. | American Heart Journal (2024) |
- | - | - | Akihiro Tobe, Ireland |
| EL6. | Transcatheter aortic valve replacement for noncalcified aortic regurgitation. Where are we now? | EL6. | REC: Inteventional Cardiology (2024) |
- | - | - | Ignacio J. Amat Santos, Spain |
| EL5. | Bicuspid aortic valve: one of the last remaining challenges for the percutaneous treatment of aortic valve disease | EL5. | Revista Española de Cardiología (2023) |
- | - | - | Pilar Jimenez Quevedo, Spain |
| EL4. | Neocommissural/ Coronary Alignment with a Novel Balloon Expandable Transcatheter Aortic Valve First-in-Human Experience | EL4. | JACC: Cardiovascular Interventions (2023) |
32 Patients | - | - | Pruthvi C.Revaiah, Ireland |
| EL3. | Transcarotid transcatheter aortic valve implantation with a novel balloon expandable Myval™ THV under the local anesthesia |
EL3. | Journal of Geriatric Cardiology (2022) |
1 Patient | - | - | Hüseyin Ayhan, Turkey |
| EL2. | Transcatheter Pulmonary Valve Replacement With 32-mm Balloon-Expandable Prosthesis: Another Strategy in Mildly Dilated RVOT | EL2. | JACC: Cardiovascular Interventions (2021) |
- | - | - | Marco B. Ancona, Italy |
| EL1. | (Intermediate) size matters | EL1. | International Journal of Cardiology (2021) |
1 Patient | - | - | Won-Keun Kim, Germany |
| Case Images (02) | |||||||
| CI 2. | Transcatheter Aortic Valve in FailingMechanical Aortic Valve | CI 1. | JACC (2024) | 1 Patient | - | - | Mario García Gómez, Spain |
| CI 1. | Valve-in-Valve TAVR for Large Degenerated Bioprosthetic Valves:The Added Value of XL-32 mm MyVal Octacor | CI 1. | Canadian Journal of Cardiology (2024) | 1 Patient | - |
- | Mariano Pellicano, Italy |
| Systematic Review (01) | |||||||
| SR 1. | The novel balloon-expandable Myval transcatheter heart valve: systematic review of aortic, mitral, tricuspid and pulmonary indications | SR 1. | Revista Española de Cardiología (2024) | 74 Patients | - |
- | Mario Garcia Gomez, Spain |
| Review Articles (08) | |||||||
| RA 8. | Myval Transcatheter Heart Valve: The Future of Transcatheter Valve Replacement and Significance in Current Timeline | RA 8. | Journal of Clinical Medicine (2024) | - | - |
- |
Teoman Kilic, Turkey |
| RA 7. | A novel balloon-expandable transcatheter aortic valve bioprosthesis: Myval and Myval Octacor | RA 7. | Expert Review of Cardiovascular Therapy (2024) | - | - |
- |
Carolina Montonati,Italy |
| RA 6. | Myval: a novel transcatheter heart valve for the treatment of severe aortic stenosis | RA 6. | Interventional Cardiology Review, Research, Resources (2023) |
- | - |
- |
Ashok Seth, India |
| RA 5. | Prosthesis tailoring for Patients undergoing transcatheter aortic valve implantation | RA 5. | Journal of Clinical Medicine (2023) |
- | - |
- |
Pier Pasquale Leone, USA |
| RA 4. | An update on new generation transcatheter aortic valves and delivery systems | RA 4. | Journal of Clinical Medicine (2022) |
- | - |
- |
Gloria Santangelo, Italy |
| RA 3. | Choice of transcatheter heart valve: should we select the device according to each patient’s characteristics or should it be “one valve fits all”? | RA 3. | Annals of Translational Medicine (2020) |
- | - |
- |
Matthias Renker, Germany |
| RA 2. | Myval transcatheter heart valve system in the treatment of severe symptomatic aortic stenosis | RA 2. | Future Cardiology (2020) | - | - |
- |
Samin K Sharma, USA |
| RA 1. | Current status of transcatheter aortic valve replacement in India | RA 1. |
Cardiovascular Diagnosis and Therapy (2019) |
- | - |
- |
Puneet Gupta, India |
| Scientific Letter (01) | |||||||
| SL 1. | Balloon-expandable Myval transcatheter aortic valve implantation. First experience in Spain |
SL 1. | Revista Espanola de Cardiologia (2020) |
2 Patients | - |
Discharge | Sandra Santos-Martınez, Spain |
| Scientific Report (01) | |||||||
| SR 1. | Angulation and curvature of aortic landing zone affect implantation depth in transcatheter aortic valve implantation |
SR 1. | Scientific Report (2024) |
81 Implants | Observational, retrospective and single-center registry |
Index Procedure | Riccardo Gorla, Italy |
| Study Protocols (02) | |||||||
| SP 2. | Randomized comparison of TAVI valves: The Compare-TAVI trial | SP 2. | American Heart Journal (2024) |
- | RCT | - | Christian Juhl Terkelsen, Denmark |
| SP 1. | Rationale and design of a randomized clinical trial comparing safety and efficacy of Myval transcatheter heart valve versus contemporary transcatheter heart valves in Patients with severe symptomatic aortic valve stenosis: The LANDMARK trial |
SP 1. | American Heart Journal (2021) |
- | Prospective, randomized, multi-national, multi-centre, open-label, non-inferiority trial | |
Hideyuki Kawashima, Ireland |
| Comment (02) | |||||||
| C 2. | Myval Balloon-Expandable Prosthesis in Argentina: Time to Take the Bull by the Horns | NA | Revista Argentina de Cardioangiología Intervencionista (2024) | 300 Patients | Prospective multi-center registry | Post-procedure | Federico Blanco, Argentina |
| C 1. | New-generation Myval transcatheter heart valve in severe aortic stenosis | C 1. | THE LANCET (2024) |
384 Patients | RCT | 30 Days | Mariama Akodad, France |
| BioMime™ Sirolimus Eluting Coronary Stent System-Clinical Publications (Total=45 articles) | |||||||
| Original Research Articles (11) | |||||||
| OR 11. | Safety and Efficacy of BioMime Sirolimus-eluting Stent System in All-comers: Real-world Population with Coronary Artery Stenosis: MILES Global Registry | NA | Cardiology Research Journal (2024) | 771 Patients | Post-marketing, multicenter, single-arm, observational clinical registry | 2 Years | Martin Hudec, Slovakia |
| OR 10. | Real-world evidence of BioMime sirolimus-eluting stent in obstructive coronary artery disease: the meriT-2 trial | OR 10. | AsiaIntervention (2024) | 250 Patients | Prospective, single-arm, multicentre study | 5 Years | Upendra Kaul, India |
| OR 9. | Long-Term Assessment of Thin-Strut BioMime Coronary Stent System in Real-World Population at Single-Center: A Retrospective Observational Study | OR 9. | Cardiology Research (2023) |
1188 Patients | Retrospective, observational, single-center, post- marketing clinical follow-up study | 4 Years | Girish Meennahalli Palleda, India |
| OR 8. | A Randomized Controlled Trial Comparing BioMime Sirolimus-Eluting Stent with Everolimus-Eluting Stent: Two-Year Outcomes of the meriT-V Trial | OR 8. | Cardiology Research (2023) | 170 out of 256 Patients | Randomized, active-controlled, non-inferiority trial, prospective, multi-center | 2 Years | Alexandre Abizaid, Brazil |
| OR 7. | Clinical follow-up of long non-tapered sirolimus-eluting coronary stent in real-world Patients with de novo lesions.The Billar registry | OR 7. | REC Interventional Cardiology (2022) |
696 Patients | Prospective, non-randomized, multi-centre study | 1 Year | Enric Domingo Ribas, Spain |
| OR 6. | Clinical outcomes of biodegradable polymer sirolimus-eluting stent in coronary artery lesions Patients: a retrospective analysis |
OR 6. | EC Cardiology (2020) | 73 Patients | Retrospective, single-center, non-randomized and observational study |
2 Years | Binu Thankappan Gomathy, India |
| OR 5. | Single long stents versus overlapping multiple stents in the management of very long coronary lesions: comparisons of procedures and clinical outcomes | OR 5. | The Journal of Tehran University Heart Center (2019) |
124 out of 1709 Patients | Historical cohort study | 1 Year | Alireza Amirzadegan, Iran |
| OR 4. | Randomized comparison of biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting coronary stent in Patients with de novo native coronary artery lesions: the meriT-V trial |
OR 4. |
EuroIntervention |
170 out of 256 Patients | Prospective, multi-centre, randomized, open label, active-controlled, and non-inferiority trial |
9 Months | Alexandre Abizaid, Brazil |
| OR 3. | One-year outcomes of a BioMime™ sirolimus-eluting coronary stent system with a biodegradable polymer in all-comers coronary artery disease Patients: The meriT-3 study | OR 3. |
Indian Heart Journal (2016) |
1161 Patients | Retrospective, multi-center study | 1 Year | Rajendra Kumar Jain, India |
| OR 2. | Late angiographic and clinical outcomes of the novel BioMime™ sirolimus-eluting coronary stent with ultra-thin cobalt-chromium platform and biodegradable polymer for the treatment of diseased coronary vessels:results from the prospective, multi-centre meriT-2 clinical trial | OR 2. |
AsiaIntervention (2016) |
250 Patients | Prospective, non randomised, single-arm, multi-centre study | 1 Year | Ashok Seth, India |
| OR 1. | First-in-human evaluation of the novel BioMime™ sirolimus-eluting coronary stent with bioabsorbable polymer for the treatment of single de novo lesions located in native coronary vessels-results from the meriT-1 trial | OR 1. | EuroIntervention (2013) | 30 Patients | Prospective, non-randomised, single-arm, single-centre study | 1 Year | Sameer Dani, India |
| Meta-Analysis (02) | |||||||
| MA 2. | Long-term follow-up after ultrathin vs. conventional 2nd generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials | MA 2. | European Heart Journal (2021) | 170 out of 256 Patients | Meta-analysis of 16 trials that randomized 20,701 Patients | 2.5 Years (mean follow- up) |
Mahesh V. Madhavan, USA |
| MA 1. | Newer generation ultra-thin strut drug- eluting stents versus older second- generation thicker strut drug-eluting stents for coronary artery disease: a meta-analysis of randomized trials. | MA 1. | Circulation (2018) | 170 Patients out of 11,658 Patients | Meta-analysis of 10 trials that randomized 11,658 Patients | 1 Year | Sripal Bangalore, USA |
| Abstracts (16) | |||||||
| AB 16. | Strut coverage of the ultrathin BioMime™ stent: a single-centre experience from the MILES-UK registry | AB 16. | EuroIntervention (2020) | 28 Patients | Prospective, OCT analysis | 3 Months | Sudipta Chattopadhyay, United Kingdom |
| AB 15. | Primary efficacy and safety outcomes of a sirolimus-eluting thin-strut coronary stent system in all-comer Patients undergoing PCI:the MILES-UK registry | AB 15. | EuroIntervention (2020) | 752 Patients | Prospective, non-randomized, multi-center, open label, observational registry | 9 Months | Ian Menown, United Kingdom |
| AB 14. | Safety and efficacy of sirolimus-eluting stent system in all-comers real-world population with coronary artery stenosis: the MILES-GLOBAL study | AB 14. | EuroIntervention (2020) | 520 Patients | Multi-center, prospective, single-arm, open-label study | 1 Year | Martin Hudec, Slovakia |
| AB 13. | Safety and performance of the biodegradable polymer-coated ultrathin strut sirolimus-eluting coronary stent system for very long lesions: 12-month experience in real-world clinical practice |
AB 13. | EuroIntervention (2020) | 216 Patients | Retrospective, single-centre study | 2 Years | Vivek Jindal, India |
| AB 12. | Clinical outcomes from real-world Patients treated with biodegradable polymer coated ultrathin-strut sirolimus-eluting coronary stent system BioMime™ GBPR | AB 12. | EuroIntervention (2020) | 1003 Patients | Retrospective, single centre study | 2 Years | Vishal Batra, India |
| AB 11. | One-year clinical outcomes in Patients implanted with biodegradable polymer coated ultra-thin strut sirolimus-eluting coronary stent system for the treatment of very long (≥40mm) lesions | AB 11. | Journal of the American College of Cardiology (2019) | 216 Patients | Retrospective single-center study | 1 Year | Mohit Gupta, India |
| AB 10. | Safety and efficacy of sirolimus-eluting stent system in all-comers real-world population with coronary artery stenosis: the MILES-GLOBAL study | AB 10. | Journal of the American College of Cardiology (2019) | 520 Patients | Multi-centre, prospective, single-arm, open-label study |
1 Year | Martin Hudec, Slovakia |
| AB 9. | Twelve-months clinical outcomes comparing biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting coronary stents in Patients with de novo native coronary artery lesions: the meriT-V randomized trial | AB 9. | Journal of the American College of Cardiology (2018) | 170 out of 256 Patients |
Prospective, multi-centre, randomized, active controlled, non-inferiority clinical trial |
1 Year | Alexandre Abizaid, Brazil |
| AB 8. | Single long stent vs. overlapping multiple stents in the management of very long coronary lesions: comparison of success rates and one-year clinical outcomes |
AB 8. | EuroIntervention (2018) | 124 out of 1709 Patients | Historical cohort study | 441 ± 361 Days | A.Amirzadegan, Iran |
| AB 7. | Efficacy and safety of an ultrathin strut sirolimus eluting stent with biodegradable polymer in all-comers Patients undergoing coronary intervention | AB 7. | European Heart Journal Supplement (2018) |
588 Patients | Prospective, non-randomised, multi-centre, open label, observational registry | 9 Months | Ian Menown, United Kingdom |
| AB 6. | Three-year clinical outcomes of BioMime™ sirolimus-eluting coronary stent system with a biodegradable polymer in coronary artery disease Patients: a long-term follow-up of the meriT-2 study | AB 6. | Journal of the American College of Cardiology (2017) | 250 Patients | Prospective, multi-center study |
3 Years | Ashok Seth, India |
| AB 5. | How to make a deal with distal left main coronary artery type A trifurcation lesion | AB 5. | Journal of the American College of Cardiology (2017) | 1 Patient | Case study | Procedural Details | Yusra Pintaningrum, Indonesia |
| AB 4. | Efficacy of the novel BioMime™ sirolimus-eluting stents with a biodegradable polymer in the treatment of de novo coronary lesions: an angiographic sub-analysis of the combined meriT-1 and meriT-2 prospective clinical trials |
AB 4. | Journal of the American College of Cardiology (2013) | 280 Patients | Sub-analysis of combined meriT-1 and meriT-2 prospective clinical trials | Angiographic analysis at 8 months of both studies | Ricardo A. Costa, Brazil |
| AB 3. | First-in-human evaluation of a novel sirolimus-eluting stent with a bioabsorbable polymer for the treatment of single, de novo, non-complex coronary lesions | AB 3. | Journal of the American College of Cardiology (2012) | 30 Patients | Prospective, non-randomized, single-arm, single-center study | 8-month angiographic and 1-year clinical follow-up | Erlon de Abreu Silva, Brazil |
| AB 2. | Impact of the new BioMime™ sirolimus-eluting stent in complex Patients of daily practice-preliminary results of the meriT-2 study | AB 2. | Journal of the American College of Cardiology (2012) | 242 Patients | Prospective, non-randomized, multi-center study | 8-month angiographic and 1-year clinical follow-up | Erlon de Abreu-Silva, Brazil |
| AB 1. | Moving towards biomimicry-development of novel BioMime™ sirolimus eluting coronary stent system | AB 1. |
The American Journal of Cardiology (2011) |
250 Patients | Single-arm, multi-center study | 1-month clinical outcome and 8-month angiographic outcomes |
Ashok Seth, India |
| Review Articles (05) | |||||||
| RA 5. | Ultrathin struts drug-eluting stents: a state-of-the-art review | RA 5. | Journal of Personalized Medicine (2022) |
- | - | - | Attilio Leone, Belgium |
| RA 4. | Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents | RA 4. | Journal of Cardiology (2018) | - | - | - | Jason Nogic, Australia |
| RA 3. | Innovative DES technologies from Meril | RA 3. | Minerva Cardioangiologica (2015) | - | - | - | Sanjeev Bhatt, India |
| RA 2. | Advantages of novel BioMime™ sirolimus eluting coronary stent system. Moving towards biomimicry | RA 2. | Minerva Cardioangiologica (2012) | - | - | - | Upendra Kaul, India |
| RA 1. | Moving towards Biomimicry-the development of the novel BioMime™ sirolimus eluting coronary stent system | RA 1. | European Cardiology Review (2010) |
- | - | - | Ashok Seth, India |
| Case Reports (08) | |||||||
| CR 8. | Cuspal dissection of aorta during percutaneous coronary intervention to left anterior descending artery managed successfully | CR 8. | IHJ Cardiovascular Case Reports (2018) |
1 Patient | - | Post-procedural | Shilpa Jayaprakash, India |
| CR 7. | Bifurcation stenting. It’s easy. That’s what I thought |
CR 7. | Journal of the American College of Cardiology (2016) | 1 Patient | - | Post-procedural | Mohan Ramachandran, Malaysia |
| CR 6. | Inter-coronary communication in chronic total occlusion: in search of recognition | CR 6. | Indian Heart Journal (2016) | 1 Patient | - | 6 Months | Mohit Gupta, India |
| CR 5. | Chronic total occlusion intervention with no-flow tackled successfully | CR 5. | Journal of the American College of Cardiology (2015) | 1 Patient | - | Post-procedural | Arvind Kumar Kandoria, India |
| CR 4. | Ostial circumflex stenting through left main-LAD stent: a challenge of access in tortuous complex circumflex anatomy | CR 4. | Journal of the American College of Cardiology (2015) | 1 Patient | - | Procedural Details | Gurunath P. Parale, India |
| CR 3. | In-situ intra procedure left main coronary artery thrombosis | CR 3. | Journal of the American College of Cardiology (2014) | 1 Patient | - | Procedural Details | Puneet Verma, India |
| CR 2. | A percutaneous coronary intervention complication: coronary perforation | CR 2. | Journal of Turgut Ozal Medical Center (2013) |
1 Patient | - | Procedural Details | Abdulmek Yildiz, Turkey |
| CR 1. | IVUS guided stenting in moderate looking proximal coronary lesion |
CR 1. | Journal of Indian College of Cardiology (2013) |
1 Patient | - | Post-procedural | Aniket Puri, India |
| Review Report/Scientific Reports (02) | |||||||
| RR 2. | Comparison of overexpansion capabilities and thrombogenicity at the side branch ostia after implantation of four different drug eluting stents | RR 2. | Nature (2020) | - | - | - | Pawel Gasior, Poland |
| RR 1. |
BioMime a sirolimus-eluting coronary stent system for the treatment of Patients with de novo coronary lesions-meriT-1 report | RR 1. | Interventional Cardiology Review, Research, Resources (2011) |
30 Patients | Prospective, single-arm, single-center study |
1 Year | Clinical Trial Department, Meril Life Sciences, India |
| Commentary (01) | |||||||
| C 1. | Very long stent technology: clinical and practical value | C 1. |
Future Cardiology (2013) |
- | - | - | Ian Menown, United Kingdom |
|
BioMime Branch™ Sirolimus Eluting Coronary Side Branch Stent System-Clinical Publication (Total= 02 article) |
|||||||
| Original Research Article (01) | |||||||
| OR 1. | Coronary Bifurcation Lesion Treatment with the BioMime™ Branch Sirolimus-Eluting Coronary Side-Branch Stent System: A Single-Center Experience | OR 1. | Cardiovascular Revascularization Medicine (2024) | 58 Patients | Retrospective, single-center study | 18 Months |
Antonio L. Bartorelli, Italy |
| Abstract (01) | |||||||
| AB 1. | BioMime™ Branch-1: a randomized comparison of sirolimus-eluting coronary side branch stent systems and everolimus-eluting stent systems to assess safety and performance in Patients with de novo coronary bifurcation lesions |
AB 1. | EuroIntervention (2020) | 18 out of 24 Patients | Prospective, active-control, open-label, multi-center, randomized clinical trial |
6 Months |
Sethuraman Selvamani, |
| BioMime™ Morph Sirolimus Eluting Tapered Coronary Stent System-Clinical Publications (Total=32 articles) | |||||||
| Original Research Articles (12) | |||||||
| OR12. | Long-Term Safety and Performance of BioMime™ Morph Sirolimus-Eluting Coronary Stent System for Very Long Coronary Lesions | OR12. | Cardiology Research (2024) | 88 Patients | Prospective, single-center, observational, real-world, post-marketing surveillance study | 3 Years | Suresh V. Patted, India |
| OR11. | Real-world experience with a 60 mm long stent in the setting of primary percutaneous coronary intervention |
OR11. | Heart Views (2022) |
88 Patients | Retrospective, observational analysis | 1 Year | Babu Thevan, Kingdom of Bahrain |
| OR10. | Percutaneous Intervention in Diffuse Coronary Disease: Overlapping Versus Single Very Long Stent Technique. Results From the OVERLONG Registry | OR10. | Angiology (2021) |
678 Patients | Observational, retrospective, and single-center study | Median follow-up 31 months |
Martín Negreira-Caamaño, Spain |
| OR9. | One-year outcomes of novel BioMime™ Morph tapered stent in long and multiple coronary artery lesions |
OR9. | Anatolian Journal of Cardiology (2021) |
172 Patients | Observational, retrospective, single-center study | 1 Year | Yash Paul Sharma, India |
| OR8. | Feasibility and outcomes of left main to branch vessel PCI with novel tapered coronary stent in a tertiary care center: a real-world experience | OR8. | Cardiovascular and Hematological Disorders Drug Targets (2021) |
41 Patients | Prospective, non-randomised, single-centre study |
Median follow-up 20 months |
T.R.Raghu, India |
| OR7. | Real-world experience with a tapered biodegradable polymer-coated sirolimus-eluting stent in Patients with long coronary artery stenosis | OR7. | Cardiology Research (2020) |
272 Patients | Prospective, observational, and multi-centre study |
1 Year | Alessandro Lupi, Italy |
| OR6. | Clinical experience with 12-month follow-up in Patients after implantation of a novel long tapered sirolimus drug-eluting stent | OR6. | Advances in Interventional Cardiology (2019) | 32 Patients | Prospective clinical cohort study | 1 Year | Jakub Podolec, Poland |
| OR5. | Feasibility of implanting 50-60 mm-tapered drug eluting stents in chronic total occlusions | OR5. | Cardiovascular Revascularization Medicine (2019) | 51 out of 54 Patients |
Retrospective, single-arm study | A median follow-up of 330 (149-551) days |
Gema Miñana, Spain |
| OR4. | Comparison of clinical outcomes between very long stents and overlapping stents for the treatment of diffuse coronary disease in real clinical practice | OR4. | Cardiovascular Revascularization Medicine (2018) | 628 Patients | Single-centre, retrospective, observational study |
Median follow-up of 20 months |
Alfonso Jurado Román, Spain |
| OR3. | Clinical outcomes of novel long-tapered sirolimus-eluting coronary stent system in real-world Patients with long diffused de novo coronary lesions | OR3. | Cadiology Research (2018) |
362 Patients | Retrospective, non-randomized, multi-centre study |
1 Year | Suresh V. Patted, India |
| OR2. | First report of the use of long-tapered sirolimus-eluting coronary stent for the treatment of chronic total occlusion with the hybrid algorithm | OR2. | Catheterization Cardiovascular Interventions (2018) |
49 out of |
Observational retrospective study | 303 ± 179 Days |
Carlo Zivelonghi, The Netherlands |
| OR1. | First experience with the use of extra-long (40 to 60 mm) sirolimus-eluting stents in Patients with diffuse long coronary lesions |
OR1. | Kardilogiya (2017) |
85 Patients | Prospective, single-centre study | 1 Year | Yu G Matchin, Russia |
| Abstracts (08) | |||||||
| AB8. | Longitudinal stent deformation detected on coronary CT in the novel BioMime™ 60mm long sirolimus-eluting tapered stent | AB8. | EuroIntervention (2020) | 20 Patients | Prospective, single-centre study | 6-9 Months | Silvia Homs, Spain |
| AB7. | Clinical outcome of the world’s first tapered sirolimus-eluting coronary stent system for long coronary lesions: a real-world experience |
AB7. | EuroIntervention (2020) | 435 Patients | Prospective, single-arm, multi-centre, real-world study | 1 Year | Deepak Davidson, India |
| AB6. | First Experience with very long coronary drug eluting stent |
AB6. | Journal of the American College of Cardiology (2019) | 63 Patients | Retrospective study |
1-3 Months | Farhat Fouladvand, Italy |
| AB5. | Initial experience with the novel BioMime™ Morph 40-60 mm long sirolimus-eluting tapered stent in long coronary lesions | AB5. | EuroIntervention (2018) | 55 Patients | Prospective, single-centre study |
200 ± 50 Days | Anirban Choudhary, United Kingdom |
| AB4. | Multicenter clinical outcomes of hybrid tapered sirolimus-eluting coronary stent system with biodegradable polymer in long diffuse de novo coronary artery lesions |
AB4. | EuroIntervention (2018) | 362 Patients | Retrospective, multi-center, non-randomized study |
6 Months | Suresh V.Patted, India |
| AB3. | Real World Experience of the BioMime™ Morph tapered stent in a Tertiary Care Hospital | AB3. | Journal of the American College of Cardiology (2018) | 122 Patients | Retrospective observational study | 26 Months | Sanjai Pattu Valappil, India |
| AB2. | Experience of the management of complex long lesion by Indigenous BioMime™ Morph tapering stents | AB2. | Journal of the American College of Cardiology (2017) | 52 Patients | Prospective, observational study | 9 Months | Manotosh Panja, India |
| AB1. | Long term outcome after revascularization of long coronary artery lesions with very long or overlapping stents. Insights from the propensity score matched registry |
AB1. | Journal of the American College of Cardiology (2017) | 123 out of 377 Patients |
Prospective, multi-centre registry | 2 Years | Piotr Buszman, Poland |
| Case Reports (09) | |||||||
| CR9. | Use of BioMime™ Morph stent in treating left main triple vessel disease: a case report |
CR 9. | The Egyptian Heart Journal (2020) | 1 Patient | - | 6 Months | Yash Paul Sharma, India |
| CR8. | Successful treatment of tandem calcific right coronary artery stenoses with 50 mm tapered BioMime™ Morph stent guided by intravascular ultra sound and rotablation using a sheath less guide via the radial access |
CR 8. | IHJ Cardiovascular Case Report (2019) |
1 Patient | - | 1 Year | Baskar Sekar, United Kingdom |
| CR7. | Acute stent loss and its retrieval of a long, tapering Morph stent in a tortuous, calcified lesion | CR 7. | Cardiology Research (2018) | 1 Patient | - | Post-procedural | Santosh Kumar Sinha, India |
| CR6. | Tapered stents in long diffusely diseased coronary arteries-our experience | CR 6. | Journal of the American College of Cardiology (2017) | 1 Patient | - | 2 Years | T.R. Raghu, India |
| CR5. | The perfect storm | CR 5. | Journal of the American College of Cardiology (2017) | 1 Patient | - | Post-procedural | Jayakhanthan Kolanthaivelu, Malaysia |
| CR4. | Management of long complex CTO in LCX by indigenous BioMime™ Morph tapering stents from Meril | CR 4. | Journal of the American College of Cardiology (2017) | 1 Patient | - | Post-procedural | Manotosh Panja, India |
| CR3. | Intravascular ultrasonography guided 60-mm long drug-eluting tapered stent implantation in a long-calcified lesion in a patient with stable coronary artery disease | CR 3. | Advances in International Cardiology (2017) |
1 Patient | - | Post-procedural | Jakub Podolec, Poland |
| CR2. | First in Poland, unique 60-mm long single drug eluting tapered stent implantation in a patient with unstable angina |
CR 2. | Polish Heart Journal (2017) | 1 Patient | - | Post-procedural | Jakub Podolec, Poland |
| CR1. | A report of successful procedural, clinical, and angiographic outcomes with a tapered stent of a patient in naturally tapered coronary vessel | CR 1. | Journal of Clinical and Diagnostic Research (2017) |
1 Patient | - | 1 Year | Rajendra Kumar Premchand, India |
| Short Report (01) | |||||||
| SR1. | Initial Experience with the novel BioMime 60mm-long sirolimus- eluting tapered stent system in long coronary lesions |
SR 1. | EuroIntervention (2017) |
50 Patients | Prospective clinical cohort study | Median follow-up 275 Days | Ernesto Valero, Spain |
| Commentary (01) | |||||||
| C1. | Innovative DES technologies from Meril |
C1. | Minerva Cardiology and Angiology (2015) |
- | - | - | Sanjeev Bhatt, India |
| Editorial (01) | |||||||
| E1. | Treatment of long coronary lesions with single stent: BioMime Morph sirolimus-eluting tapered coronary stent system | E1. | Heart India (2018) |
- | - | - | Suresh V. Patted, India |
|
BioMime™ Aura Sirolimus Coronary Eluting Stent System-Clinical Publications (Total=02 articles) |
|||||||
| Original Research Article (01) | |||||||
| OR1. | Endovascular reconstruction of popliteal and infrapopliteal arteries for limb salvage and wound healing in Patients with critical limb ischemia-A retrospective analysis | OR 1. | Indian Heart Journal (2016) | 34 Patients | Retrospective analysis | 3 Months | Uday B. Khanolkar, India |
| Case Report (01) | |||||||
| CR1. | Multiple coronary microfistulas between left anterior descending artery and left ventricle following myocardial infarction |
CR 1. |
Heart India (2017) | 1 Patient | - | Post-procedural | Sulaiman S, India |
| Evermine50™ EES-Drug Eluting Stent-Clinical Publications (Total=12 articles) | |||||||
| Original Research Articles (05) | |||||||
| OR 5. | Clinical safety and performance of the world’s thinnest strut Evermine50™ Everolimus-eluting stent: A 24-month follow-up of Evermine50 EES-1 study | OR.5 | AsiaIntervention (2024) | 118 Patients | Prospective, single-arm, multi-center study | 2 Years | Sivaprasad K, India |
| OR 4. | Procedural safety and outcome of ultrathin strut stents (<60 μm) in the management of very long coronary artery stenosis (>30 mm)- A retrospective real-world study |
OR.4 | American Journal of Cardiovascular Disease (2020) | 65 out of 156 Patients | Retrospective analysis, observational study | 8.4 ± 13.9 months mean follow up |
Soumya Patra, India |
| OR 3. | Clinical outcomes of ultrathin strut biodegradable polymer-coated everolimus eluting stent in Patients with coronary artery disease | OR.3 | ARYA Atherosclerosis (2020) |
171 Patients | Retrospective study, single-arm, all-comers, single-center study |
1 Year | Suresh V. Patted, India |
| OR 2. | Clinical safety and efficacy of world’s thinnest (50μm), very long (>40 mm) everolimus eluting stent among real world Patients |
OR.2 | American Journal of Cardiovascular Disease (2020) | 711 Patients | Prospective, observational study | 1 Year | Santosh Kumar Sinha, India |
| OR 1. | Clinical outcomes of world’s thinnest (50μm) strut biodegradable polymer coated everolimus eluting coronary stent system in real-world Patients | OR.1 | Cardiology Research (2018) |
251 Patients | Prospective, single-arm, single-center, post marketing study | 6 Months | Suresh V. Patted, India |
| Editorial (02) | |||||||
| E 2. | Less is more: a new “thin-king” for DES? | E.2 | - | - | - | Azfar G. Zaman, United Kingdom | |
| E 1. | Biodegradable polymer Evermine50™ everolimus eluting coronary stent system with ultrathin (50μm) strut |
E.1 | Integrative Clinical Medicine (2018) |
- | - | - | Suresh V. Patted, India |
| Case Series (01) | |||||||
| CS 1. | Device embolization during trans-radial percutaneous coronary intervention: Various approaches. A case series |
CS.1 | IHJ Cardiovascular Case Reports (2021) |
3 Patients | - | - | Nagamani Alur Chikkabasavaiah, India |
| Abstracts (04) | |||||||
| AB 4. | One-year clinical outcomes of ultrathin strut everolimus-eluting coronary system (50µm) for treatment of patient with de novo coronary artery lesions |
AB.4 | AsiaIntervention (2019) | 171 Patients | Retrospective, single-arm, observational study |
1 Year | Suresh V. Patted, India |
| AB 3. | 1-year clinical outcomes after percutaneous coronary intervention with biodegradable polymer ultra-thin strut everolimus-eluting coronary stent system | AB.3 | Journal of the American College of Cardiology (2019) | 251 Patients | Prospective, single-arm, single-center, real-world study |
1 Year | Suresh V. Patted, India |
| AB 2. | Initial experience with ultrathin strut biodegradable polymer-coated everolimus-eluting coronary stent in coronary artery disease Patients | AB.2 | Journal of the American College of Cardiology (2018) | 110 Patients | Prospective, non-randomized, multi-center study | 6 Months | K. Sivaprasad, India |
| AB 1. | Clinical outcomes of ultrathin strut biodegradable polymer-coated everolimus-eluting coronary stent system in treatment of patient with de novo coronary artery lesions | AB.1 | EuroIntervention (2018) | 171 Patients | Single-arm, single-center, non-randomized study | 1 Year | Suresh V. Patted, India |
| MeRes100™ Sirolimus Eluting BioResorbable Vascular Scaffold System-Clinical Publications (Total=19 articles) | |||||||
| Original Research Articles (04) | |||||||
| OR4. | Imaging and two-year clinical outcomes of thin strut sirolimus-eluting bioresorbable vascular scaffold: the MeRes-1 extend trial |
OR4. | Catheterization and Cardiovascular Interventions (2020) |
64 Patients | Prospective, multi-centre, single-arm, open-label study |
2 Years | Alexandre Abizaid, Brazil |
| OR3. | Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial |
OR3. | EuroIntervention (2019) | 108 Patients |
Prospective, multi-center, single-arm, open-label clinical trial |
3 Years | Ashok Seth, India |
| OR2. | Pharmacokinetic study of sirolimus-eluting bioresorbable vascular scaffold system for treatment of de novo native coronary lesions: a sub-study of MeRes-1 trial |
OR2. | Cardiology Research (2018) | 10 Patients | Prospective, single-arm, open-label pilot study |
90 days | Praveen Chandra, India |
| OR1. | First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial | OR1. | EuroIntervention (2017) | 108 Patients | Prospective, multi-center, single-arm study | 1 Year | Ashok Seth, India |
| Abstracts (09) | |||||||
| AB9. | The MeRes-1 Extend trial: 2-year clinical and 6-month imaging outcomes of thin-strut sirolimus-eluting BRS in Patients with de novo coronary artery lesions | AB 9. | Journal of the American College of Cardiology (2020) | 64 Patients | Prospective, multi-centre, single-arm study |
Imaging follow-up at 6 months and clinical follow-up at 2 years | Alexandre Abizaid, Brazil |
| AB8. | Clinical and imaging outcomes of thin-strut sirolimus eluting BRS in Patients with de novo coronary artery lesions: the MeRes-1 extend trial | AB 8. | EuroIntervention (2020) | 64 Patients | Prospective, multi-centre, single-arm study |
Angiographic follow-up at 6 months and clinical follow-up upto 24 months |
Alexandre Abizaid, Brazil |
| AB7. | Implantation of thin-strut sirolimus-eluting bioresorbable vascular scaffold in Patients with de novo coronary artery lesions: 2-year clinical and 6-month imaging outcomes of the MeRes-1 extend trial |
AB 7. | Journal of the American College of Cardiology (2019) | 64 Patients | Multi-centre, prospective, single-arm study | Imaging follow-up at 6 months and clinical follow-up at 2 years |
Alexandre Abizaid, Brazil |
| AB6. | Real world follow-up one year of the novel MeRes100 | AB 6. | Journal of the American College of Cardiology (2018) |
65 Patients (81 MeRes100 implanted) |
Prospective, single-centre registry | 1 Year and OCT at 9 months | Marcos Ortega, Ecuador |
| AB5. | Two-year clinical and imaging outcomes of thin strut sirolimus-eluting bioresorbable vascular scaffolds in de novo coronary artery lesions: the MeRes-1 trial | AB 5. | Journal of the American College of Cardiology (2018) | 108 Patients | Prospective, multi-centre, single-arm study | 2 Years | Ashok Seth, India |
| AB4. | Real world performance of the novel MeRes100™ | AB 4. | Journal of the American College of Cardiology (2017) | 34 Patients (41 MeRes100 implanted) | Prospective, single-centre, registry |
9 Months | Marcos Ortega, Ecuador |
| AB3. | Favorable outcomes for systemic pharmacokinetic study of sirolimus-eluting bioresorbable vascular scaffold system in treating de novo native coronary artery lesion: A sub study of MeRes-1 Trial |
AB 3. | Journal of the American College of Cardiology (2017) | 10 Patients | Prospective, multi-centre study | 90 Days | Ashok Seth, India |
| AB2. | First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial | AB 2. | Journal of the American College of Cardiology (2017) | 108 Patients | Prospective, multi-centre, first-in-human study |
Angiographic follow-up at 6-months, clinical follow-up at 12 months |
Ashok Seth, India |
| AB1. | Quantitative angiographic analysis in Patients with de novo native coronary artery lesions treated with novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 Trial |
AB 1. | European Heart Journal (2017) |
108 Patients | First-in-man | Angiographic follow-up at 6-and 24 months |
Ricardo Costa, Brazil |
| Review Articles (03) | |||||||
| RA3. | Fully bioresorbable vascular scaffolds: Lessons learned and future directions | RA 3. | Nature Reviews Cardiology (2019) |
- | - | - | Hiroyuki Jinnouchi, United States of America |
| RA2. | Bioresorbable coronary scaffolds: deployment tips and tricks and the future of the technology |
RA 2. | Methodist DeBakey Cardiovascular Journal (2018) |
- | - | - | J. Ribamar Costa, Brazil |
| RA1. | Bioresorbable scaffold The emerging reality and future directions |
RA 1. | Circulation Research (2017) |
- | - | - | Yohei Sotomi, Netherlands |
| Book Chapter (01) | |||||||
| BC1. | MeRes100™ -A sirolimus eluting bioresorbable vascular scaffold system |
BC 1. | In Bioresorbable Scaffolds (2017) | - | - | - | Ashok Seth, India |
| Editorial/ Editorial Commentary (02) | |||||||
| E1. | A fresh look at bioresorbable scaffold technology: Intuition pumps | E 1. | Indian Heart Journal (2017) | - | - | - | Sundeep Mishra, India |
| EC2. | Can the vanishing stent reappear? Fix the technique, or fix the device? | EC 2. | Journal of the American College of Cardiology (2017) | - | - | - | Spencer B. King, USA |
| Mozec™ Rx PTCA Balloon Dilation Catheter-Clinical Publications (Total=05 articles) | |||||||
| Original Research Articles (02) | |||||||
| OR2. | Clinical outcomes of a non-compliant balloon dilatation catheter: Mozec™ NC study | OR2. | International Journal of Environmental Research and Public Health (2022) |
57 of 140 Patients | Post-marketing, single-centre, single-arm, retrospective study |
10.40 ± 0.26 months |
Akshyaya Pradhan, India |
| OR1. | Complex coronary interventions with the novel Mozec™ CTO balloon: The Mozart registry |
OR 1. |
Clinical Medicine Insights: Cardiology (2015) |
41 Patients | Prospective non- randomized, single-arm registry |
1 Year | Alessandro Lupi, Italy |
| Abstract (01) | |||||||
| AB1. | How to make a deal with distal left main coronary artery type a trifurcation lesion | AB 1. | Journal of the American College of Cardiology (2017) | 1 Patient | - | - | Yusra Pintaningrum, Indonesia |
| Review Article (01) | |||||||
| RA1. | Drug-coated balloons: technologies and clinical applications | RA 1. | Current Pharmaceutical Design (2018) | - | - | - | Huiying Ang, Singapore |
| Case Report (01) | |||||||
| CR1. | Persistent stent thrombosis in a patient with non-ST-segment elevation myocardial infarction and mild COVID-19 | CR 1. | Journal of Coronary Artery Disease (2022) |
1 Patient | - | Procedural Details | Mehmet Rasih Sonsoz, Turkey |
| Metafor™ Sirolimus Eluting Coronary Stent System-Clinical Publications (Total=05 articles) | |||||||
| Original Research Articles (03) | |||||||
| OR 3. | Twelve-month clinical outcomes of biodegradable polymer-coated sirolimus-eluting coronary stent in real-world Patients: a single-center experience |
OR 3. | Indian Heart Journal (2021) | 141 Patients | Retrospective, single-centre, post-marketing, observational study | 1 Year | Pankaj Jariwala, India |
| OR 2. | Safety and performance of sirolimus-eluting coronary stent system with biodegradable polymer: a retrospective analysis in real-world patient population |
OR 2. | World Journal of Cardiovascular Diseases (2017) | 127 Patients | Retrospective, non-randomized, single-center study | 3.6 ± 0.6 Years | Vithala Surya Prakasa Rao, India |
| OR 1. | One-year clinical outcomes of biodegradable polymer-coated sirolimus-eluting coronary stent system in Patients with coronary artery disease |
OR 1. | World Journal of Cardiovascular Diseases (2017) | 251 Patients | Retrospective, single-center, observational, post-marketing study |
1 Year | Sridhar Kasturi, India |
| Abstracts (02) | |||||||
| AB 2. | Safety and clinical performance of biodegradable polymer-coated sirolimus-eluting coronary stent in real-world Patients |
AB 2. | EuroIntervention (2020) | 141 Patients | Observational, single-center, post-marketing, retrospective study |
1 Year | Pankaj Jariwala, India |
| AB 1. | One-year clinical outcomes of biodegradable polymer coated sirolimus-eluting coronary stent system in Patients with coronary artery disease |
AB.1 | Journal of the American College of Cardiology: Cardiovascular interventions (2017) |
251 Patients | Retrospective, single center, observational, post-marketing study | 1 Year | Shridhar Kasturi, India |
| NexGen™ Bare Metal Stent-Clinical Publication (Total=01 article) | |||||||
| Abstract (01) | |||||||
| OR 1. | Evaluation of safety and efficacy of NexGen-an ultrathin strut and hybrid cell design cobalt-chromium bare metal stent implanted in a real-life patient population-the Polish NexGen™ Registry | OR.1 | Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej (2016) | 383 Patients | A prospective, multi-center registry | 1 Year | Krzysztof Milewski, Poland |
| Osum™ Cobalt Chromium Coronary Stent System-Clinical Publication (Total=01 article) | |||||||
| Original Research Article (01) | |||||||
| OR 1. | Clinical safety and performance of novel ultra-thin strut cobalt chromium bare metal stent implanted in real-world Patients with coronary artery disease | OR.1 | International Journal of Current Research (2018) |
467 Patients | Observational, non-randomized, retrospective, single-arm study | 2 Years | Mahesh Basarge, India |
| Dafodil™ Pericardial Bioprosthesis-Clinical Publications (Total=02 articles) | |||||||
| Original Research Articles (02) | |||||||
| OR 2. | Three-year Outcomes of Surgical Valve Replacement with Dafodil™ Pericardial Bioprosthesis: Dafodil™-1 Trial | OR 2. | Frontiers in Cardiovascular Medicine (2024) |
136 Patients | First-in-human, prospective, multi-center study | 3 Years |
C.S. Hiremath, India |
| OR 1. | Clinical outcomes and hemodynamic performance of Dafodil™ aortic and mitral pericardial bioprosthesis: 1-year results from Dafodil-1 first-in-human trial | OR 1. | Journal of Cardiothoracic Surgery (2020) |
60 Patients | First-in-human, prospective, single-arm, and multi-center trial | 1 Year | C.S. Hiremath, |
| CREDENCE™ BtK Sirolimus Eluting Bioresorbable Peripheral Scaffold System-Clinical Publication (Total=01 article) | |||||||
| Abstract (01) | |||||||
| AB 1. | 12-month clinical outcomes of sirolimus-eluting bioresorbable peripheral scaffold system following percutaneous transluminal angioplasty of below-the-knee arteries in Patients with critical limb ischaemia: the CREDENCE™ BtK-1 study |
AB.1 | EuroIntervention (2020) | 30 Patients | First-in-man, prospective, multi-centre and open-label study | 1 Year | Vimal Someshwar, India |
| Menox™ Liquid Embolic System-Clinical Publications (Total=07 articles) | |||||||
| Original Research Article (02) | |||||||
| OR 2. | Comparison of a Novel Liquid Embolic System with Commonly Used Embolic Agents in the Endovascular Treatment of Intracranial Dural Arteriovenous Fistulas: A Single-Center Experience | OR.2 | Journal of Clinical Medicine (2024) | 11 out of 19 Patients | Single center, retrospective study | 12 Months | Zarko Nedeljkovic, Serbia |
| OR 1. | Intermixed dimethyl-sulfoxide based non adhesive liquid embolic agents delivered serially via the same micro catheter for cerebral AVM treatment | OR.1 | American Journal of Neuroradiology (2020) | 16 Patients | Single-centre, prospective study | Angiographic mean follow-up of 5.1 months | Alexander Sirakov, Bulgaria |
| Case Report (02) | |||||||
| CR 2. | Embolization Using the Novel Menox Liquid Embolic System for Arteriovenous Fistulas: A Case Report | CR 2. | Journal of Clinical and Medical Image (2023) |
1 Patient | - | 6 Months | Audrius Sirvinskas, Lithuania |
| CR 1. | Endovascular treatment of a post-traumatic pseudoaneurysm arising from a ruptured posterior tibial artery with Menox™ A case report |
CR.1 | Radiology Case Reports (2021) |
1 Patient | - | 6 Months | Christina Aslanidi, Greece |
| Case Series (02) | |||||||
| CS 2. | Initial experience with the new ethylene vinyl alcohol copolymer based liquid embolic agent Menox™ in the endovascular treatment of cerebral arteriovenous malformations | CS 2. | Journal of NeuroInterventional Surgery (2018) |
24 Patients | Pilot study, retrospective analysis of prospectively collected data | 6 Months | Stanimir Sirakov, Bulgaria |
| CS 1. | Extending endovascular embolization to type A spinal peri-medullary arteriovenous fistula using liquid embolic agent: technical nuances, challenges and initial results | CS 1. | World Neurosurgery (2018) | 3 Cases | - | - | Virender Malik, India |
| Review Article (01) | |||||||
| RA 1. | Glue, Onyx, Squid or PHIL? Liquid Embolic Agents for the Embolization of Cerebral Arteriovenous Malformations and Dural Arteriovenous Fistulas | RA.1 | Clinical Neuroradiology (2022) |
- | - | - | Dominik F. Vollherbst, Germany |
| Obtura™Vascular Closure Device- Clinical Publication (Total=01 article) | |||||||
| Original Research Article (01) | |||||||
| OR 1. | Comparing Obtura Vascular Closure Device to Manual Compression for Achieving Hemostasis After Percutaneous Transfemoral Procedures: A Randomized Study | OR 1. |
Journal of Endovascular Therapy (2024) | 134 out of 268 Patients | Prospective, randomized, controlled, multi-center trial | 3 Months | Tom Devasia, India |
| Mammoth Balloon Catheter-Clinical Publication (Total= 01 article) | |||||||
|
Original Research Articles (01) |
|||||||
| OR 01. | Performance of the Mammoth Balloon Catheter in Patients with Severe Aortic Valve Stenosis Undergoing Percutaneous Treatment | OR 01. | Journal of Clinical Medicine (2024) | 121 Patients | Retrospective, single-center cohort analysis | Post-procedure | Silvia Moscardelli, Italy |
| ORTHOPEDIC (Total= 16 articles) | |||||||
| Freedom® Total Knee System-Clinical Publications (13) |
|||||||
| Original Research Articles (11) | |||||||
| OR 11. | Comparative mid-term evaluation of unilateral and bilateral total knee arthroplasty utilizing metal-backed components: An assessment of functional and clinical outcomes |
OR 11. | Journal of Orthopaedic Reports (2024) |
408 Patients | Prospective, single-arm post-marketing surveillance study | 3 Years | Ponnanna Karineravanda Machaiah, India |
| OR 10. | Comparison of Early Results Between Bone-Conserving and Conventional High-Flexion Posterior-Stabilized Total Knee Arthroplasty |
NA | Journal of Orthopedic Research and Therapy (2024) |
295 Patients in Freedom TKA group | Prospective study | Mean follow up of 3.5 years | Young-Hoo Kim, Republic of Korea |
| OR 9. | A comprehensive comparative study on mid-term clinical and functional outcomes in Indian patients following bilateral total knee arthroplasty: assessing the impact of body mass index on post-total knee arthroplasty results | OR 9. | International Journal of Research in Orthopaedics (2024) | 190 Patients | Prospective, multi-center observational study | 3 Years | Karineravanda M. Ponnanna, India |
| OR 8. | Age wise comparative analysis of Patients undergoing total knee arthroplasty: a multicenter indigenous experience | OR 8. | International Journal of Research in Orthopaedics (2024) |
300 Patients | Prospective, multi-centre, real-world study | 3 Years | Ravi Teja Rudraraju, India |
| OR 7. | A multi-centre retrospective study of the impact of body mass index on clinical and functional outcomes of total knee arthroplasty: An Indian prospective | OR 7. | Journal of Orthopaedic Reports (2024) |
259 Patients | Multi-centre retrospective analysis | 3 Years | Kunal Arneja, India |
| OR 6. | Efficacy of the pre‑operative three‑dimensional (3D) CT scan templating in predicting accurate implant size and alignment in robot assisted total knee arthroplasty |
OR 6. | Indian Journal of Orthopaedics (2022) |
30 Patients | Prospective, single-center study | - | Sanjay Bhalchandra Londhe, India |
| OR 5. | Early results of bone‑conserving high flexion posterior‑stabilized total knee system in Indian population |
OR 5. | Indian Journal of Orthopaedics (2022) |
208 Patients | Prospective, continuous series study |
5 Years | Sanjay Bhalchandra Londhe, India |
| OR 4. | Education, engagement, and provision of empathy by trained counselor enhances the patient satisfaction after total knee arthroplasty |
OR 4. | Journal of Clinical Orthopaedics and Trauma (2020) |
200 Patients | Prospective, randomized study | 52 Weeks | Sanjay Bhalchandra Londhe, India |
| OR 3. | Restoration of femoral condylar anatomy for achieving optimum functional expectations: continuation of an earlier study at 5-year minimum follow-up | NA | Reconstructive review (2019) | 172 Patients | Prospective, single-center study | 5 Years | Sridhar Durbhakula, India |
| OR 2. | Clinical evaluation of efficacy and performance of all-poly tibial Freedom® total knee system for treating osteoarthritis Patients: three-year follow up study |
OR 2. | Journal of Clinical and Diagnostic Research (2017) | 158 Patients | Retrospective, post-marketing study, single-center | 3 Years | Avatar Singh, India |
| OR 1. | Restoration of femoral condylar anatomy for achieving optimum functional expectations: component design and early results |
NA | Reconstructive review (2016) |
172 Patients | Prospective, non-randomized, single-center study | 2 Years with average follow-up of 3.8 ± 0.9 Years |
Sridhar Durbhakula, India |
| Commentary (01) | |||||||
| CO 1. | Challenges in successful management of haemophilic knee arthropathy: our experience in a tertiary center | CO.1 | Journal of Orthopaedics (2022) |
24 Patients | - |
1 Year | Mohan Thadia, India |
| Abstract (01) | |||||||
| AB 1. | One-stage total knee arthroplasty with long stemmed tibia for traumatic tibial diaphysis fracture with co-existing osteoarthritis of the knee | AB.1 | Orthopaedics Proceedings (2022) | 3 Patients | - | 1 Year | Sanjay Bhalchandra Londhe, India |
| Cuvis Joint- Clinical Publications (04) | |||||||
| Original Research Articles (04) | |||||||
| OR 4. | Analysis of robotspecifc operative time and surgical team anxiety level and its efect on alignment during robotassisted TKA | OR 4. | Journal of Robotic Surgery (2024) |
40 Patients | 40 Patients | Post-procedural | Sanjay Bhalchandra Londhe, India |
| OR 3. | Comparison of Time Taken in Conventional versus Active Robotic-Assisted Total Knee Arthroplasty | OR 3. | Clinics in Orthopedic Surgery (2024) | 30 Patients | Prospective study | 30 Days | Sanjay Bhalchandra Londhe, India |
| OR 2. | Intraoperative Safety of an Autonomous Robotic System for Total Knee Replacement: A Review of 500 Cases in India | OR 2. | Indian Journal of Orthopaedics (2023) | 500 Patients | Single-center, retrospective, observational study | 30 Days | Chandrashekar P, India |
| OR 1. | Efficacy of the Preoperative ThreeDimensional (3D) CT Scan Templating in Predicting Accurate Implant Size and Alignment in Robot Assisted Total Knee Arthroplasty | OR 1. | Indian Journal of Orthopaedics (2023) | 30 Patients | Prospective study, single center study | Prospective study, single center study | Prospective study, single center study |
| ENDOSURGERY (Total=11 articles) | |||||||
| MERIZELLETM Absorbable Hemostat- Clinical Publication | |||||||
| Original Research Article (01) | |||||||
| OR1. | The Safety and Effectiveness of MERIZELLE Oxidized Regenerated Cellulose in Achieving Hemostasis Across Various Surgical Procedures-A Prospective, Multi-Center, Post-Marketing Surveillance Study | NA |
Journal of Wound Care (2024) | 189 Patients |
Prospective, Multi-Center, Post-Marketing Surveillance Study | 6 Months | Amey Patankar, India |
| MITSU™ ABP Polyglactin 910 Suture-Clinical Publications (01) | |||||||
| Study Protocol (01) | |||||||
| SP1. | Evaluation of safety and efficacy of Polyglactin 910 suture in surgical incision closure: clinical study protocol for a randomized controlled trial | SP 1. |
International Journal of Clinical Trials (2018) | 122 Patients |
Prospective, multi-center, randomized, controlled, comparative, post-marketing and single-blinded | 6 Months | Asha Dixit, India |
| MIRUS™ Disposable Haemorrhoids Stapler- Clinical Publications (02) | |||||||
| Original Research Articles (02) | |||||||
| OR2. | Clinical outcomes of stapled hemorrhoidopexy using a novel three-row stapler for grade III/IV hemorrhoids: A single-center experience with literature review | OR 2. | Journal of Clinical Images and Medical Case Reports (2023) | 77 Patients | Retrospective single centre, cohort study | 2 Years | M Sadiq Kazi, India |
| OR1. | Comparison of conventional (CH) vs stapled haemorrhoidectomy (SH): three-yearss experience |
OR 1. |
Annals of International Medical and Dental Research (2017) |
150 Patients | Retrospective and comparative study | 1 Year | Kumar Gaurav, India |
| Mirus™ Circular Stapler- Clinical Publications (02) | |||||||
| Original Research Article (01) | |||||||
| OR1. | Our initial experience of three versus two rows circular stapler devices for stapled hemorrhoidopexy: a single institution review of 224 cases |
OR 1. |
International Surgery Journal (2020) |
224 Patients | Retrospective, observational, cohort study | - | Paritosh Gupta, India |
| Study Protocol Clinical Trial (01) | |||||||
| SP1. | Uni-center, patient-blinded, randomized, 12-month, parallel group, non-inferiority study to compare outcomes of 3-row vs 2-row circular staplers for colorectal anastomosis formation after low anterior resection for rectal cancer |
SP 1. |
Medicine (2019) | 154 Patients | Prospective, non-inferiority, 2-armed, parallel-group | Nikita A. Nekliudov, Russia |
|
| Fiona™ Intrauterine Contraceptive Device-Clinical Publication (01) | |||||||
| Original Research Article (01) | |||||||
| OR1. | Safety and performance of a levonorgestrel-releasing intrauterine contraceptive device: one-year outcomes of Fiona-1 clinical registry | OR. 1 |
Journal of the Indian Medical Association (2019) | 309 Patients | Prospective, open-label, single-arm post-marketing study | 1 Year | Jagruti Desai, India |
| FILASILK™ Silk Suture-Clinical Publication (01) | |||||||
| Original Research Article (01) | |||||||
| OR1. | The safety and efficacy of clipless versus conventional laparoscopic cholecystectomy-our experience in an Indian rural center |
OR 1. |
MAEDICA Journal of Clinical Medicine (2018) |
160 Patients |
Prospective study | 2 Months | Rikki Singal, India |
| MEGASORB™ Polyglycolic Acid Suture-Clinical Publication (01) | |||||||
| Original Research Article (01) | |||||||
| OR1. | Comparative evaluation of two antibacterial-coated resorbable sutures versus non coated resorbable sutures in periodontal flap surgery: A clinico-microbiological study |
OR 1. |
Indian Society of Periodontology (2019) | 10 out of 30 Patients | Randomized controlled double-blinded study | 1 Month | Prerna Ashok Karde, India |
| MEGASORBPLUS™ Polyglycolic Acid Suture with Chlorhexidine-Clinical Publication (01) | |||||||
| Original Research Article (01) | |||||||
| OR1. | Comparative evaluation of two antibacterial-coated resorbable sutures versus non coated resorbable sutures in periodontal flap surgery: A clinico-microbiological study | OR 1. |
Indian Society of Periodontology (2019) | 10 out of 30 Patients | Randomized controlled double-blinded study | 1 Month | Prerna Ashok Karde, India |
| MEGASORB RAPID™ Polyglycolic Acid Suture-Clinical Publication (01) | |||||||
| Original Research Article (01) | |||||||
| OR1. | Comparative evaluation of two antibacterial-coated resorbable sutures versus non coated resorbable sutures in periodontal flap surgery: A clinico-microbiological study |
OR 1. |
Indian Society of Periodontology (2019) | 10 out of 30 Patients | Randomized controlled double-blinded study | 1 Month | Prerna Ashok Karde, India |
| ABSOMESH™ Polyglecaprone 25/ Polypropylene Mesh-Clinical Publication (01) | |||||||
| Original Research Article (01) | |||||||
| OR1. | A comparative study of open vs laparoscopic repair in umbilical and para umbilical hernias | OR 1. |
Journal of Dental and Medical Sciences (2019) |
70 out of 156 Patients | Prospective, observational study | Post-operative | P. Venkata Buddha, India |
| DIAGNOSTICS (Total= 3 articles) | |||||||
| EXIMO™ Blood Glucose Monitoring System-Clinical Publication (Total=01 article) | |||||||
| Original Research Article (01) | |||||||
| OR1. | A post-marketing surveillance study to evaluate performance of the EXIMO™ blood glucose monitoring system | OR 1. | Journal of Clinical and Diagnostic Research (2017) | 1005 Patients |
Non-randomized, single-center, post-marketing study | - | Sonia R. Chandnani, India |
| CelQuant 360™ Automated Haematology Analyser-Clinical Publication (Total=01 article) | |||||||
| Original Research Article (01) | |||||||
| OR1. | Comparison between haematological parameters by the Merilyzer Celquant 360™ automated haematology analyser and Sysmex XP-100 haematology analyser with them manual methods | OR 1. | European Journal of Biomedical and Pharmaceutical Sciences (2018) |
- | Comparative, Cross-sectional study | - | Krishnajyoti Goswami, Malaysia |
| ABFIND COVID-19 Neutralizing Antibody Rapid Test-Clinical Publication (Total=01 article) | |||||||
| Original Research Article (01) | |||||||
| OR1. | A prospective, single-center study to evaluate the clinical performance of Meril ABFind in individuals vaccinated against Covid-19 | OR 1. | medRxiv (Preprint) (2022) |
62 Patients | Single centre, prospective study | - | Jayanti Shastri, India |
Disclaimer:
This page is under Construction.